Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Higgins

Showing results (411-420 of 427) with videos related to

Pageof 43
Sort By:
Arthritis and Rheumatism|February 1, 2011
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter seriesPeter A Nigrovic, Melissa Mannion, Femke H M Prince, et al.
Arthritis and Rheumatism|December 21, 2011
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritisCarol A Wallace, Edward H Giannini, Steven J Spalding, et al.
The Journal of Rheumatology|May 3, 2014
Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictorsCarol A Wallace, Edward H Giannini, Steven J Spalding, et al.
Rheumatology (Oxford, England)|December 22, 2005
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international studyF Zulian, B H Athreya, R Laxer, et al.
Arthritis Care & Research|April 17, 2012
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized sclerodermaSuzanne C Li, Kathryn S Torok, Elena Pope, et al.
Nature Medicine|February 17, 2015
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseasesRebecca C Coll, Avril A B Robertson, Jae Jin Chae, et al.
American Journal of Human Genetics|May 16, 2007
Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European AmericansYan Yang, Erwin K Chung, Yee Ling Wu, et al.
Arthritis and Rheumatism|May 1, 2009
Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohortLaura E Schanberg, Christy Sandborg, Huiman X Barnhart, et al.
Lupus|September 24, 2010
Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohortS P Ardoin, L E Schanberg, C Sandborg, et al.
Arthritis and Rheumatism|October 28, 2011
Use of atorvastatin in systemic lupus erythematosus in children and adolescentsL E Schanberg, C Sandborg, H X Barnhart, et al.
Pageof 43

Showing results (411-420 of 427) with videos related to

Sort By:
Pageof 43
Arthritis and Rheumatism|February 1, 2011
Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter seriesPeter A Nigrovic, Melissa Mannion, Femke H M Prince, et al.
Arthritis and Rheumatism|December 21, 2011
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritisCarol A Wallace, Edward H Giannini, Steven J Spalding, et al.
The Journal of Rheumatology|May 3, 2014
Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictorsCarol A Wallace, Edward H Giannini, Steven J Spalding, et al.
Rheumatology (Oxford, England)|December 22, 2005
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international studyF Zulian, B H Athreya, R Laxer, et al.
Arthritis Care & Research|April 17, 2012
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized sclerodermaSuzanne C Li, Kathryn S Torok, Elena Pope, et al.
Nature Medicine|February 17, 2015
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseasesRebecca C Coll, Avril A B Robertson, Jae Jin Chae, et al.
American Journal of Human Genetics|May 16, 2007
Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European AmericansYan Yang, Erwin K Chung, Yee Ling Wu, et al.
Arthritis and Rheumatism|May 1, 2009
Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohortLaura E Schanberg, Christy Sandborg, Huiman X Barnhart, et al.
Lupus|September 24, 2010
Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohortS P Ardoin, L E Schanberg, C Sandborg, et al.
Arthritis and Rheumatism|October 28, 2011
Use of atorvastatin in systemic lupus erythematosus in children and adolescentsL E Schanberg, C Sandborg, H X Barnhart, et al.
Pageof 43